Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Targeting specific T cells may help treat alopecia areata.

The muscle damage was caused by T-cell large granular lymphocytic leukemia, not dermatomyositis.

Tacrolimus effectively promotes hair regrowth in an alopecia areata mouse model.

ILC1-like cells may contribute to hair loss in alopecia areata and could be new treatment targets.

Activating TLR9 helps heal large wounds and regrow hair by involving a specific type of immune cell.

Cell-based therapy using specific immune cells may help treat alopecia areata by promoting hair regrowth.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

Increasing regulatory T cells may help treat alopecia areata by reducing autoimmunity and promoting hair growth.

People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.

Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.

Activating TLR3 boosts autophagy gene expression in skin cells.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Epidermal resident memory T cells play a crucial role in skin immunity and disease understanding.

Targeting the AhR pathway may help treat alopecia areata.

Alopecia areata involves specific immune cells, offering potential treatment targets.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Dormant melanoma cells in mice interact minimally with memory T cells due to a suppressive tumor environment.

Catalytic antibodies are early indicators and active participants in the development of systemic lupus erythematosus.

Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

A man's red tattoo caused a skin reaction and hair loss in his beard, which improved after treatment.

Cats likely have a reactive skin condition, while dogs may have a more complex, possibly cancerous one.

Patients with alopecia areata have higher levels of certain immune markers, suggesting new treatment targets.

Feline cutaneous lymphocytosis is likely reactive, while canine cutaneous lymphocytosis needs more study to understand its nature.

Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.

IL-2 treatment causes skin eruptions and other reversible side effects, and may play a role in psoriasis.

Malt1 protease is essential for regulatory T cell function and could be targeted to boost antitumor immunity.